A phase I double blind placebo controlled trial to evaluate the safety and immunogenicity of the Aventis Pasteur ALVAC-HIV (vCP205) administered to the groin area versus the deltoid area
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2012
At a glance
- Drugs HIV vaccine vCP205 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 16 Sep 2008 Actual start date added (June 2006) as reported by ClinicalTrials.gov.
- 16 Sep 2008 Planned end date added (1 Sep 2008) as reported by ClinicalTrials.gov.